Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies
MedComm,
Год журнала:
2025,
Номер
6(3)
Опубликована: Март 1, 2025
Pulmonary
hypertension
(PH)
stands
as
a
tumor
paradigm
cardiovascular
disease
marked
by
hyperproliferation
of
cells
and
vascular
remodeling,
culminating
in
heart
failure.
Complex
genetic
epigenetic
mechanisms
collectively
contribute
to
the
disruption
pulmonary
homeostasis.
In
recent
years,
advancements
research
technology
have
identified
numerous
gene
deletions
mutations,
addition
bone
morphogenetic
protein
receptor
type
2,
that
are
closely
associated
with
remodeling
process
PH.
Additionally,
modifications
such
RNA
methylation,
DNA
histone
modification,
noncoding
RNAs
been
shown
precisely
regulate
PH
molecular
networks
cell-type-specific
manner,
emerging
potential
biomarkers
therapeutic
targets.
This
review
summarizes
analyzes
roles
currently
genes
factors
PH,
emphasizing
pivotal
role
long
ncRNAs
its
regulation.
it
examines
current
clinical
preclinical
therapies
for
targeting
these
explores
new
treatment
strategies.
Язык: Английский
Crosstalk of glutamine metabolism between cancer-associated fibroblasts and cancer cells
Cellular Signalling,
Год журнала:
2025,
Номер
133, С. 111874 - 111874
Опубликована: Май 15, 2025
Язык: Английский
3,4-Dimethoxycinnamic acid from coffee silverskin biowaste ameliorates bleomycin-induced pulmonary fibrosis via modulating caveolin-1-dependent activation of NF-κB, TGF-β1/Smad3, and ERK1/2 signaling pathways
Toxicology and Applied Pharmacology,
Год журнала:
2025,
Номер
501, С. 117414 - 117414
Опубликована: Май 25, 2025
Язык: Английский
Role of inflammation in endothelial responses in Pulmonary Hypertension
Biomedicine & Pharmacotherapy,
Год журнала:
2025,
Номер
188, С. 118206 - 118206
Опубликована: Май 28, 2025
Язык: Английский
3D-printed endovascular scaffold loaded with miR-199a-5p promotes the functional repair of atherosclerosis
Materials Technology,
Год журнала:
2024,
Номер
39(1)
Опубликована: Ноя. 27, 2024
Among
deaths
related
to
cardiovascular
disease
(CVD),
arteriosclerosis
accounts
for
three-quarters
of
the
total.
The
most
common
treatment
is
revascularization
through
implantation
endovascular
scaffolds.
However,
metal
scaffolds
currently
available
are
non-biodegradable,
which
can
lead
rejection
reactions.
In
this
study,
we
have
developed
a
CMCS-PEI/miR
polysaccharide
nucleic
acid
nanodrug
loaded
with
miR-199a-5p
first
time.
exhibits
good
blood
compatibility,
successfully
transfects
cells,
and
induces
apoptosis
vascular
endothelial
cells.
Additionally,
PCL/GO
composite
excellent
mechanical
properties
biocompatibility
were
fabricated
using
3D
printing
technology.
This
technology
allows
customisation
meet
needs
individual
patients.
3D-printed
CMCS-PEI/miRNA
effectively
induce
showing
great
potential
in
promoting
functional
repair
preventing
restenosis.
Язык: Английский